Market Overview: Multiple Myeloma   27-page PDF document
$299.00

Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Log in to unlock full preview.
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Arrow   Click main image to view in full screen.

Market Overview: Multiple Myeloma (PDF)

PDF document 27 Pages

#1 in Oncology $299.00
Explore the comprehensive market overview of multiple myeloma, detailing growth drivers, key therapies, and expert insights. Created by industry specialists.
Add to Cart
  


Immediate download
Editable with PDF editor
Free lifetime updates

BENEFITS OF THIS PDF DOCUMENT

  1. The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025
  2. Currently approved therapies will continue to have a meaningful impact on the multiple myeloma treatment algorithm and market sales
  3. Major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025

HEALTHCARE PDF DESCRIPTION

This product (Market Overview: Multiple Myeloma) is a 27-page PDF document, which you can download immediately upon purchase.

The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025, with major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025. Growth will be fueled by the continued uptake and label expansions of current therapies and the expected market entry of four novel, premium-priced therapies. Immunomodulatory agents are, and will remain, the dominant drug class throughout the forecast period and will capture more than 50% of major-market sales in 2025.

Currently approved therapies will continue to have a meaningful impact on the multiple myeloma treatment algorithm and market sales. Lenalidomide is set to retain its position as the sales-leading agent in multiple myeloma, with sales expected to reach more than $11.7 billion across the seven major markets in 2025. Continued penetration of the R/R setting will provide significant revenue, as will its label expansion in the first-line setting, in addition to use in combination with recently approved and emerging agents, such as carfilzomib, ixazomib, elotuzumab, daratumumab, and pembrolizumab.
Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PDF: Market Overview: Multiple Myeloma PDF (PDF) Document, pharmzolgas


$299.00
Explore the comprehensive market overview of multiple myeloma, detailing growth drivers, key therapies, and expert insights. Created by industry specialists.
Add to Cart
  

ABOUT THE AUTHOR

Author: pharmzolgas
Additional documents from author: 3

Ask the Author a Question

You must be logged in to contact the author.

Click here to log in Click here register

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials

 
"Last Sunday morning, I was diligently working on an important presentation for a client and found myself in need of additional content and suitable templates for various types of graphics. Flevy.com proved to be a treasure trove for both content and design at a reasonable price, considering the time I "

– M. E., Chief Commercial Officer, International Logistics Service Provider
 
"My FlevyPro subscription provides me with the most popular frameworks and decks in demand in today’s market. They not only augment my existing consulting and coaching offerings and delivery, but also keep me abreast of the latest trends, inspire new products and service offerings for my practice, and educate me "

– Bill Branson, Founder at Strategic Business Architects
 
"As an Independent Management Consultant, I find Flevy to add great value as a source of best practices, templates and information on new trends. Flevy has matured and the quality and quantity of the library is excellent. Lastly the price charged is reasonable, creating a win-win value for "

– Jim Schoen, Principal at FRC Group
 
"I am extremely grateful for the proactiveness and eagerness to help and I would gladly recommend the Flevy team if you are looking for data and toolkits to help you work through business solutions."

– Trevor Booth, Partner, Fast Forward Consulting
 
"Flevy is now a part of my business routine. I visit Flevy at least 3 times each month.

Flevy has become my preferred learning source, because what it provides is practical, current, and useful in this era where the business world is being rewritten.

In today's environment where there are so "

– Omar Hernán Montes Parra, CEO at Quantum SFE
 
"The wide selection of frameworks is very useful to me as an independent consultant. In fact, it rivals what I had at my disposal at Big 4 Consulting firms in terms of efficacy and organization."

– Julia T., Consulting Firm Owner (Former Manager at Deloitte and Capgemini)
 
"Flevy.com has proven to be an invaluable resource library to our Independent Management Consultancy, supporting and enabling us to better serve our enterprise clients.

The value derived from our [FlevyPro] subscription in terms of the business it has helped to gain far exceeds the investment made, making a subscription a no-brainer for any growing consultancy – or in-house strategy team."

– Dean Carlton, Chief Transformation Officer, Global Village Transformations Pty Ltd.
 
"FlevyPro has been a brilliant resource for me, as an independent growth consultant, to access a vast knowledge bank of presentations to support my work with clients. In terms of RoI, the value I received from the very first presentation I downloaded paid for my subscription many times over! The "

– Roderick Cameron, Founding Partner at SGFE Ltd


Your Recently Viewed Documents


Customers Also Like These Documents

Related Management Topics


Healthcare Cancer Integrated Financial Model Value Chain Analysis

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.